The phase 3 Exenatide-PD3 study is a UK-wide clinical trial that evaluated whether exenatide may slow the progression of Parkinson’s. Exenatide (also known as Bydureon) is a type 2 diabetes drug
The diabetes drug lixisenatide is in trials for the treatment of Parkinson’s. In France, results from a one year, phase 2 clinical trial has shown positive results suggesting that lixisenatide
The therapy, developed by Bayer’s Bluerock Therapeutics subsidiary, appeared safe and well-tolerated in a 12-person clinical trial. Published Aug. 28, 2023